Grifois
GRFS
About: Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Employees: 23,800
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
27% more capital invested
Capital invested by funds: $1.03B [Q1] → $1.32B (+$282M) [Q2]
27% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 45
20% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 6 (+1) [Q2]
7% more funds holding
Funds holding: 143 [Q1] → 153 (+10) [Q2]
0.1% more ownership
Funds ownership: 55.63% [Q1] → 55.73% (+0.1%) [Q2]
46% less call options, than puts
Call options by funds: $684K | Put options by funds: $1.26M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
JP Morgan
James Gordon
|
$10.3
|
Neutral
Maintained
|
17 Jun 2025 |
Financial journalist opinion
Based on 4 articles about GRFS published over the past 30 days
